Evidence map›Paper›PMID 42656310›Full record

ArticleFrontiers in pharmacology2026

Network pharmacology-guided identification of Rabdosia rubescent as a suppressor of laryngeal cancer via MMP9-mediated extracellular matrix remodeling: integrated

Xuefeng Wang, Guanying Ren, Yonggang Zhang, Yu Peng, Ruiyao Wang, Yang Li, Jingyu Wang, Sicong Jia, Jingyun Li, Lei Song and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xuefeng Wang *Department of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Guanying Ren *Hebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Yonggang Zhang *Department of Head and Neck Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Yu PengDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Ruiyao WangDepartment of Thoracic Surgery, Affiliated Hospital of Hebei University, Baoding, China.
Yang LiDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Jingyu WangDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Sicong JiaDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Jingyun LiDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.
Lei SongDepartment of Integrated Chinese and Western Medicine, Affiliated Hospital of Hebei University, Baoding, China.
Yan ShiHebei Key Laboratory of Cancer Radiotherapy and Chemotherapy, Department of Medical Oncology, Affiliated Hospital of Hebei University, Baoding, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Laryngeal cancer, particularly laryngeal squamous cell carcinoma (LSCC), poses a significant threat to global health, especially within Asian populations. While Methods: This study employed an integrated approach combining network pharmacology, molecular docking, and 500 ns molecular dynamics simulations to screen bioactive compounds from Results: Network pharmacology identified MMP9 as a critical therapeutic target, which was found to be significantly overexpressed in LSCC tissues. Virtual screening and MD simulations identified Cirsiliol as the most potent inhibitor among the tested phytochemicals, exhibiting a highly favorable binding free energy (ΔG Conclusion: This study establishes Cirsiliol as a potent, specific inhibitor of MMP9 derived from

Indexed as

experimental validationlaryngeal cancerMMP9molecular dockingmolecular dynamicsnetwork pharmacology

Identifiers

PMID42656310
PMCPMC13506694

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.